Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Expects M&A, Sharper Competition To Result From New Drug Policy

This article was originally published in PharmAsia News

Executive Summary

China's Health Ministry is looking to its new essential drugs policy to spur drug maker competition, along with the potential for mergers and acquisitions. The head of the ministry's program called the policy the central part of the nation's medical reform plan. He said establishing a competitive bidding process for drug makers to sell to the government means all makers of the same drug are not going to succeed. That means more mergers and acquisitions are likely to result in China, he said. Domestic generics makers are expected to be the major beneficiaries of the new policy. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts